An established market with significant unmet needs
According to independent market research we conducted, 68% of ED patients are not fully satisfied with their treatment and research shows that within just one year of treatment initiation, almost 25% of all ED patients will discontinue therapy.
There is also a subset of erectile dysfunction sufferers who would not be prescribed any of the PDE5 inhibitors due to contraindications with other medications taken by them, including those who have stable angina, a condition treated with nitrate medicines. Research conducted on behalf of Futura showed that around 20% of patients cannot take any of the PDE5 inhibitors due to contraindications with other medicines they take.
Market research indicates that only 15%-30% of men with erectile dysfunction consult a doctor. All existing treatments for erectile dysfunction require a prescription from a doctor (except for some limited products in the UK and Poland).
There are clearly significant unmet needs for ED patients. Key Opinion Leaders (KOLs) in sexual medicine are supportive of the MED3000 development programme as there has been little innovation in the ED space in recent years. An endorsement and engagement programme is under way.